Form 4: Adverum Biotechnologies Executive Acquires 85,000 Stock Options Following Performance Milestone

Setareh Seyedkazemi, Chief Development Officer of Adverum Biotechnologies, acquired 85,000 stock options after a performance condition related to the LUNA trial was met.

Summary

• This Form 4 filing reports a change in beneficial ownership for Setareh Seyedkazemi, Chief Development Officer of Adverum Biotechnologies, Inc.
• On October 3, 2023, Seyedkazemi acquired 85,000 stock options with an exercise price of $1.29.
• These options vested due to the achievement of a performance condition related to the dosing of patients in the LUNA trial.
• The Vesting Commencement Date was certified by the Issuer's Compensation Committee to have occurred on August 16, 2023.
• The options vest monthly, with full vesting occurring on the second anniversary of the Vesting Commencement Date, contingent upon continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The vesting of options indicates progress in the LUNA trial, but it's a routine event.

Positives

• The vesting of these options suggests that the LUNA trial is progressing according to plan, as a performance milestone has been met.
• The vesting of options incentivizes the Chief Development Officer to continue working towards the company's goals.

Future Outlook

The options vest monthly, with full vesting occurring on the second anniversary of the Vesting Commencement Date, contingent upon continued service.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the alignment of management's interests with those of shareholders.

Stakeholder Impact

• The vesting of options aligns the interests of the Chief Development Officer with those of shareholders, incentivizing her to work towards the success of the company and the LUNA trial.

Key Dates